# Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

> **NCT05511844** · PHASE1 · TERMINATED · sponsor: **Orum Therapeutics USA, Inc.** · enrollment: 25 (actual)

## Conditions studied

- HER2-positive Breast Cancer
- HER-2 Protein Overexpression
- HER-2 Gene Amplification
- HER2 Gene Mutation

## Interventions

- **DRUG:** ORM-5029

## Key facts

- **NCT ID:** NCT05511844
- **Lead sponsor:** Orum Therapeutics USA, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-10-03
- **Primary completion:** 2025-06-02
- **Final completion:** 2025-06-02
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2025-07-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05511844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05511844, "Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05511844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*